Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion

Bone Marrow Transplantation

Volumn 33, Issue 5, 2004, Pages 549-552

  Ogawa, N ^a   Kanda, Y ^a   Matsubara, M ^a   Asano, Y ^a   Nakagawa, M ^a   Sakata Yanagimoto, M ^a   Kandabashi, K ^a   Izutsu, K ^a   Imai, Y ^a   Hangaishi, A ^a   Kurokawa, M ^a   Tsujino, S ^a   Ogawa, S ^a   Aoki, K ^a   Chiba, S ^a   Motokura, T ^a   Hirai, H ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Continuous infusion; Cyclosporine A; Graft versus host disease; Hematopoietic stem cell transplantation

Indexed keywords

ACICLOVIR; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; TACROLIMUS; TOSUFLOXACIN;

ACUTE DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HERPES SIMPLEX; HIGH RISK PATIENT; HLA MATCHING; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYCOSIS; NEPHROTOXICITY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL TIME;

ACUTE DISEASE; ADULT; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; LEUKEMIA; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 12144287370     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704374     Document Type: Article

References (8)

1. Ruutu T, Niederwieser D, Gratwohl A et al. A survey of the prophylaxis and treatment of acute GVHD in Europe: A report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997; 19: 759-764.
2. Alvarez JS, Sacristan JA, Alsar MJ. Comparison of a monoclonal antibody fluorescent polarization immunoassay with monoclonal antibody radioimmunoassay for cyclosporin determination in whole blood. Ther Drug Monit 1992; 14: 78-80.
3. Thomas ED, Storb R, Clift RA et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975; 292: 895-902.
4. Kanda Y, Mineishi S, Saito T et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: A single-center experience in Japan. Bone Marrow Transplant 2001; 27: 437-444.
5. Gooley TA, Leisenring W, Crowley J et al. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706.
6. Nash RA, Antin JH, Karanes C et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062-2068.
7. Ratanatharathorn V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303-2314.
8. Miller KB, Schenkein DP, Comenzo R et al. Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 1994; 68: 15-20.